JY
RPRX icon

Jeff Yass’s Royalty Pharma RPRX Stock Holding History

Jeff Yass’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55M Sell
152,400
-59,400
-28% -$3.09M ﹤0.01% 3646
2026
Q1 		$10.2M Buy
211,800
+102,600
+94% +$4.49M ﹤0.01% 3094
2025
Q4 		$4.22M Sell
109,200
-227,000
-68% -$8.66M ﹤0.01% 4296
2025
Q3 		$11.9M Sell
336,200
-111,100
-25% -$4.02M ﹤0.01% 2823
2025
Q2 		$16.1M Sell
447,300
-105,100
-19% -$3.48M ﹤0.01% 2254
2025
Q1 		$17.2M Buy
552,400
+368,000
+200% +$11.7M ﹤0.01% 1882
2024
Q4 		$4.7M Sell
184,400
-1,800
-1% -$47.7K ﹤0.01% 3688
2024
Q3 		$5.27M Buy
186,200
+43,100
+30% +$1.19M ﹤0.01% 3513
2024
Q2 		$3.77M Buy
143,100
+50,300
+54% +$1.39M ﹤0.01% 3902
2024
Q1 		$2.82M Sell
92,800
-64,800
-41% -$1.91M ﹤0.01% 4634
2023
Q4 		$4.43M Buy
157,600
+20,100
+15% +$552K ﹤0.01% 3914
2023
Q3 		$3.73M Sell
137,500
-54,000
-28% -$1.6M ﹤0.01% 4023
2023
Q2 		$5.89M Sell
191,500
-127,100
-40% -$4.3M ﹤0.01% 3263
2023
Q1 		$11.5M Sell
318,600
-49,300
-13% -$1.83M ﹤0.01% 2283
2022
Q4 		$14.5M Sell
367,900
-484,700
-57% -$20.2M ﹤0.01% 1824
2022
Q3 		$34.3M Buy
852,600
+97,700
+13% +$4.17M 0.01% 1030
2022
Q2 		$31.7M Buy
754,900
+435,300
+136% +$17.8M 0.01% 1116
2022
Q1 		$12.5M Buy
319,600
+85,100
+36% +$3.34M ﹤0.01% 2266
2021
Q4 		$9.35M Buy
234,500
+88,700
+61% +$3.45M ﹤0.01% 2815
2021
Q3 		$5.27M Sell
145,800
-144,900
-50% -$5.63M ﹤0.01% 3856
2021
Q2 		$11.9M Sell
290,700
-54,900
-16% -$2.34M ﹤0.01% 2668
2021
Q1 		$15.1M Buy
345,600
+229,400
+197% +$10.9M ﹤0.01% 2228
2020
Q4 		$5.82M Buy
116,200
+50,500
+77% +$2.14M ﹤0.01% 3199
2020
Q3 		$2.76M Buy
+65,700
New +$2.82M ﹤0.01% 4011

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's RPRX Position: Q2 2026 in Review

Jeff Yass reduced its Royalty Pharma (RPRX) stake by 2.4% in Q2 2026, selling an estimated $32.5K and leaving 25,009 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #7318.

Jeff Yass first reported a position in RPRX in Q2 2020 and has held it in 21 quarters since. The position peaked at $52.8M in Q4 2024. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Jeff Yass held 25,009 shares of Royalty Pharma worth $1.4M as of Q2 2026.
  • Jeff Yass sold 624 Royalty Pharma shares in Q2 2026, an estimated $32.5K.
  • Royalty Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7318 holding.
  • Jeff Yass first reported a position in Royalty Pharma in Q2 2020 and has held it in 21 quarters since.
  • Jeff Yass's Royalty Pharma position peaked at $52.8M in Q4 2024.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.